Kriya Therapeutics vs Emulate

Side-by-side comparison of AI visibility scores, market position, and capabilities

Emulate leads in AI visibility (74 vs 36)
Kriya Therapeutics logo

Kriya Therapeutics

NicheLife Sciences & BioTech

AAV Gene Therapy Platform for Chronic Disease

Kriya Therapeutics is a gene therapy company using AAV vector engineering to develop one-time treatments for chronic diseases including diabetes and hemophilia; raised $270M total including a $150M Series C in 2022 led by Premji Invest;

AI VisibilityBeta
Overall Score
D36
Category Rank
#90 of 198
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
33
Perplexity
40
Gemini
34

About

Kriya Therapeutics is a gene therapy company founded in 2019 by Saket Bhargava and Chintan Shah, headquartered in Research Triangle Park, North Carolina. The company is building a platform for adeno-associated virus (AAV) gene therapy specifically targeting chronic metabolic and cardiovascular diseases — conditions where a single gene therapy treatment could potentially replace a lifetime of injectable or oral medications. Kriya's therapeutic thesis is that gene therapy, historically applied to rare genetic diseases, can be extended to larger-prevalence conditions like type 2 diabetes, obesity, and lipid disorders — unlocking much larger commercial markets than orphan drug gene therapy programs.

Full profile
Emulate logo

Emulate

LeaderLife Sciences & BioTech

Organ-on-Chip & Drug Development Tools

Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.

AI VisibilityBeta
Overall Score
B74
Category Rank
#8 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
73
Gemini
77

About

Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#90
Category Rank
#8
81
AI Consensus
73
stable
Trend
stable
33
ChatGPT
78
40
Perplexity
73
34
Gemini
77
36
Claude
79
39
Grok
68

Key Details

Category
AAV Gene Therapy Platform for Chronic Disease
Organ-on-Chip & Drug Development Tools
Tier
Niche
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.